What is the fair value of Pharvaris NV (NASDAQ-PHVS) stock?

The current fair value estimate for Pharvaris NV (NASDAQ-PHVS) is $39.88. This implies an estimated upside of 13.3% versus the current market price.

Is Pharvaris NV (NASDAQ-PHVS) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 13.3% versus the current market price.

What is the analyst price target for NASDAQ-PHVS stock?

The available analyst price target for Pharvaris NV (NASDAQ-PHVS) is $58.21. The analyst target implies estimated upside of 65.4%.

How is the financial health of Pharvaris NV?

The current financial health read for Pharvaris NV (NASDAQ-PHVS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Pharvaris NV's next earnings date?

The next earnings date currently listed for Pharvaris NV (NASDAQ-PHVS) is November 18, 2026.

Does Pharvaris NV (NASDAQ-PHVS) pay dividends?

The latest available data indicates no current dividend yield for Pharvaris NV (NASDAQ-PHVS).

What is the market capitalization of Pharvaris NV?

The current market capitalization listed for Pharvaris NV is 2.471 B.

What is the enterprise value of Pharvaris NV?

The current enterprise value listed for Pharvaris NV is 2.16 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Pharvaris NV?

The ticker symbol for Pharvaris NV is NASDAQ-PHVS, and the stock is listed on NASDAQ.

Where is Pharvaris NV (NASDAQ-PHVS) listed?

Pharvaris NV (NASDAQ-PHVS) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Pharvaris NV?

The current debt-to-total-capital ratio listed for Pharvaris NV is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Pharvaris NV?

The free float listed for Pharvaris NV is 62.3%. Free float helps investors understand how much of the share base is available for public trading.

Pharvaris NV (PHVS) Fair Value & Stock Analysis

Pharvaris NV (PHVS)

Pharvaris N.V. is a late-stage biopharmaceutical company focused on therapies for rare diseases with unmet medical needs, particularly conditions driven by bradykinin, including angioedema. Its main development candidate is deucrictibant, a small-molecule bradykinin B2-receptor antagonist being studied for attacks linked to bradykinin-mediated angioedema, including hereditary angioedema and acquired angioedema due to C1-inhibitor deficiency. The program is in phase 3 development, including studies for both treatment and prevention of hereditary angioedema attacks. Pharvaris is also developing extended-release tablet and immediate-release capsule formulations of deucrictibant. The company was incorporated in 2015 and is headquartered in Zug, Switzerland.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-PHVS	$39.88	13.3% Upside	Fair	$58.21	65.4% Upside	Bargain	Fair	0.0%	November 18, 2026	7.3x	2.471 B	2.16 B	0.0%	62.3%	10.2	90.9%